Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CGAS | Q8N884 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 7/20 | 0.41 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.41 |
| ▸ | NFATC1 | O95644 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.37 |
| ▸ | FLT3 | P36888 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.37 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29764637 | 0.89 | CGAS (0.51) | CGASKDM4EALDH1A1HPGDPKM | |
| SCHEMBL23600366 | 0.89 | CGAS (0.51) | CGASKDM4EALDH1A1HPGDPKM | |
| SCHEMBL3467529 | 0.80 | NTRK1 (0.56) | KDM4EALDH1A1HPGDGSK3BMAPT | |
| SCHEMBL3467353 | 0.80 | NTRK1 (0.56) | KDM4EALDH1A1HPGDGSK3BMAPT | |
| SCHEMBL3467350 | 0.80 | NTRK1 (0.56) | KDM4EALDH1A1HPGDGSK3BMAPT | |
| SCHEMBL23600437 | 0.77 | PIM1 (0.39) | KDM4EALDH1A1GSK3BDYRK1ANFATC1 | |
| SCHEMBL23578611 | 0.77 | CISD1 (0.56) | KDM4EGSK3BDYRK1AMAPTRAB9A | |
| SCHEMBL23582913 | 0.77 | DYRK1A (0.40) | GSK3BDYRK1ANFATC1CCNT1CDK9 | |
| SCHEMBL23578614 | 0.77 | CISD1 (0.56) | KDM4EGSK3BDYRK1AMAPTRAB9A | |
| SCHEMBL29764781 | 0.77 | CISD1 (0.56) | KDM4EGSK3BDYRK1AMAPTRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | claimed |
| CN-114945569-A | Pyrrolidine derivative, and pharmaceutical composition for preventing or treating beta-amyloid or Tau-protein related diseases comprising same | 延世大学校产学协力团 | 2022-08-26 | — | — | CN | claimed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2023-04-27 | — | — | US | disclosed |
| EP-4083037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | Yonsei University, University-Industry Foundation(UIF). (KR) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021133037-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | 연세대학교 산학협력단 | 2021-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129364-A1 | PYRROLIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING BETA-AMYLOID OR TAU PROTEIN-ASSOCIATED DISEASES CONTAINING SAME | MAPT, APP, PRNP | CGAS 2700/4885KDM4E 3638/4885ALDH1A1 4631/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.